Abstract
AbstractPreviously, we reported that an ANGPTL3 vaccine is a hopeful therapeutic option against dyslipidemia. In our current study, we assess durability and booster effects of that vaccine over a period representing a mouse’s lifespan. The vaccine remained effective for over one year, and booster vaccination maintained suppression of circulating triglyceride levels thereafter without major adverse effects on lungs, kidneys, or liver, suggesting vaccine efficacy and safety.
Funder
Ono Medical Research Foundation
MEXT | Japan Society for the Promotion of Science
Japan Agency for Medical Research and Development
KM Biologics Co., Ltd. and FunPep Co., Ltd.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Infectious Diseases,Pharmacology,Immunology
Reference9 articles.
1. Grundy, S. M. et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 139, e1082–e1143 (2019).
2. Mach, F. et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur. Heart J. 41, 111–188 (2020).
3. Mercep, I., Strikic, D., Sliskovic, A. M. & Reiner, Z. New Therapeutic Approaches in Treatment of Dyslipidaemia-A Narrative Review. Pharmaceuticals (Basel). 15, https://doi.org/10.3390/ph15070839 (2022).
4. Mullard, A. FDA approves first anti-ANGPTL3 antibody, for rare cardiovascular indication. Nat. Rev. Drug Discov. 20, 251 (2021).
5. Fukami, H. et al. Vaccine targeting ANGPTL3 ameliorates dyslipidemia and associated diseases in mouse models of obese dyslipidemia and familial hypercholesterolemia. Cell Rep. Med. 2, 100446 (2021).